Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00005918 | Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients | PHASE3 | COMPLETED | 730 | — | — | Jun 1, 2000 | Apr 1, 2002 | May 4, 2011 | 77 | United States, Argentina +15 |
| Name | Type | Description |
|---|---|---|
| Efavirenz | DRUG | - |
| Lamivudine | DRUG | - |
| Stavudine | DRUG | - |
Inclusion Criteria Patients may be eligible for this study if they: * Are at least 18 years old. Patients living in USA, Puerto Rico, Australia, Brazil, Singapore, and Thailand can be at least 12 years old (need consent of parent or guardian if under 18). * Have a viral load of at least 2,000 copi...